Margit Mahlapuu

PharmaSurgics is a clinical stage biotech company developing novel treatments for the prevention of harmful scarring (adhesions) after surgery. Post-surgical adhesions develop in millions of patients every year and are a source of great patient suffering and enormous healthcare expenditures. The company was founded in 2005 after extensive research done by Dr Inger Mattsby-Baltzer, PhD and Professor Kjell Olmarker MD, PhD at the Sahlgrenska Academy. PharmaSurgics is based in Göteborg, Sweden, where comprehensive in vitro and in vivo facilities have been established.

Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden.

Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden.

Pergamum AB develops, registers, markets, and trades pharmaceutical products based on therapeutic peptides. The company was founded on June 18, 2008 and is headquartered in Solna, Sweden.

AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.

ScandiCure AB develops anti-diabetic drug based on small molecule antagonists of a novel key mediator. The company was founded by Margit Mahlapuu on August 8, 2016 and is headquartered in Göteborg, Sweden.

Promore Pharma AB is a biopharmaceutical company, which engages in the development of therapeutic peptides for the bioactive wound care market. The company was founded by Mona Ståhle and Johan Heilborn on January 29, 2003 and is headquartered in Solna, Sweden.

Sixera Pharma AB conducts activities within research, development, and commercialization of pharmaceuticals. It develops treatment for Netherton syndrome. The company was founded by Jean Nordstrom on August 21, 2012 and is headquartered in Göteborg, Sweden.

Arexela AB provides scientific and technical research and development services. The CEO of the Swedish company is Margit Mahlapuu.